BioSpace News Archive

SCYNEXIS, Inc. today announced the presentation of interim data across a diverse array of infection types from its ongoing Phase 3 FURI and CARES studies, as well as the innovative study design of its ongoing Phase 3 MARIO trial of oral ibrexafungerp treatment after an intravenous (IV) echinocandin, at the 33rd Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held in Copenhagen, Denmark, April 15-18, 2023.

Cerevance today announced a poster presentation at the British Neuroscience Association (BNA) 2023 International Festival of Neuroscience in Brighton, United Kingdom being held April 23-26, 2023.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 26, at 4:30 p.m. ET to discuss first-quarter 2023 financial results and provide a general business update.

The National Comprehensive Cancer Network® and the NCCN Foundation® announced four winners for the 2023 NCCN Foundation Young Investigator Awards.

Hillstream BioPharma, Inc. has selected immune-oncology clinical research organization (CRO), OncoBay Clinical , to provide comprehensive clinical and regulatory support for the clinical development program for its lead drug candidate HSB-1216.

Invitae (NYSE: NVTA) today announced new research published in Nature describing the first use of the company’s personalized cancer monitoring (PCM) platform to demonstrate the utility of ctDNA as a biomarker for cancer recurrence in a large cohort of patients with stage I-III non-small-cell lung cancer (NSCLC) followed for up to five years.

Editas Medicine, Inc. today announced the appointment of current Independent Director Emma Reeve as Chair of the Board, effective at the Company’s next annual stockholder meeting, currently scheduled for June 1.

Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced that over 1,000 cardiac arrhythmia patients have been treated using the Genesis Robotic Magnetic Navigation system.

Prime Therapeutics LLC is proud to announce that its companies, Magellan Rx Management, LLC and Magellan Pharmacy Solutions, Inc., have earned URAC re-accreditation for Pharmacy Benefit Management.

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the first participant has been dosed in the HELIOS study, a Phase 2 clinical trial of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO]) for the treatment of Wolfram syndrome (WS).